Solid IO Secures $800K Funding to Revolutionize Precision Oncology with Organ-on-Chip Innovation

Solid IO is thrilled to announce that we have successfully raised €800,000 in our latest funding round—a significant milestone affirming our mission to revolutionize oncology and immunotherapy using cutting-edge organ-on-chip technology. As we spearhead the transformation of cancer care, our advanced patient-specific tumor models are designed to replicate the tumor microenvironment with remarkable precision. This breakthrough innovation not only provides real-time, biologically relevant data, but also empowers oncologists, researchers, and pharmaceutical innovators to make more precise treatment decisions, reducing uncertainty in drug development and clinical trials. The new investment will drive the scaling of our technology, enhance integration between scientific breakthroughs and clinical applications, and accelerate the optimization of immuno-oncology research approaches. In doing so, we are setting a new benchmark for personalized treatment pathways, fast-tracking drug R&D timelines, and paving the way toward more efficient biomarker validation processes, thereby improving patient outcomes worldwide. Based in Helsinki, Finland, our collaborative efforts extend across top cancer clinics, research centers, and global biopharmaceutical leaders, ensuring that precision oncology reaches those who need it most. With this funding, Solid IO is poised to push the boundaries of modern cancer therapies, bolstering our comprehensive platform that bridges the gap between laboratory insights and real-world patient care. As we bring the next era of precision oncology into focus, we invite visionary partners and forward-thinking investors to join us in our mission to redefine cancer care and ensure that advanced, patient-specific therapeutic options are universally accessible.